NASDAQ:FULC Fulcrum Therapeutics Q2 2026 Earnings Report $3.78 +0.02 (+0.40%) As of 01:44 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fulcrum Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.24Beat/MissMissed by -$0.10One Year Ago EPSN/AFulcrum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFulcrum Therapeutics Announcement DetailsQuarterQ2 2026Date7/30/2026TimeBefore Market OpensConference Call DateThursday, July 30, 2026Conference Call Time7:00AM ETUpcoming EarningsFulcrum Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, October 28, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Fulcrum Therapeutics Earnings HeadlinesKaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law ViolationsSeptember 16 at 1:51 PM | markets.businessinsider.comKaplan Fox Advises Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of an Investigation Into Potential Securities Law ViolationsSeptember 16 at 4:44 AM | theglobeandmail.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 18 at 1:00 AM | TradeSmith (Ad)Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law ViolationsSeptember 12, 2026 | theglobeandmail.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)September 9, 2026 | globenewswire.comFULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersSeptember 5, 2026 | businesswire.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases that affect skeletal muscle and other tissues. The company uses its FulcrumSeek drug-discovery platform to identify molecular targets and potential therapies for conditions in which the underlying biology is well characterized but treatment options remain limited. Fulcrum’s lead product candidate is losmapimod, an investigational oral therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle-wasting disorder. Losmapimod is designed to inhibit p38 alpha and p38 beta mitogen-activated protein kinases and reduce expression of DUX4, a gene believed to play a central role in FSHD. The company has also pursued programs in other genetic and rare diseases, including sickle cell disease, although its development pipeline may change as clinical and strategic priorities evolve. Founded in 2016 and headquartered in Waltham, Massachusetts, Fulcrum conducts research and clinical development activities primarily through collaborations and studies involving patients and healthcare providers in the United States and other regions. The company is led by President and Chief Executive Officer Robert J. Gould, Ph.D., who is also a co-founder.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
